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Abstract: The Hippo pathway plays an important role in the development of hepatocellular 
carcinoma (HCC). The present study aimed at exploring the genetic variants of Hippo pathway-
related genes and their association with HCC prognosis. A total of 331 HCC patients who tested 
positive for hepatitis B surface antigen were recruited in this study. None of the patients had prior 
surgical treatment. Twelve potentially functional single-nucleotide polymorphisms (rs7317471 
and rs9509492 in LATS2; rs4810446, rs2267853, rs8000, and rs6073627 in MST1; rs10955176 
in MST2; and rs16861979, rs2043550, rs16861985, rs1055153, and rs7630434 in TAZ) in the 
Hippo pathway were genotyped from patients’ peripheral leukocytes using the Sequenom 
MassARRAY iPLEX platform. Cox proportional hazard models and log-rank test were used for 
the survival analyses. LATS2 rs7317471 C.T polymorphism was significantly associated with 
decreased risk of death in HCC using the dominant model (adjusted hazard ratio [HR] =0.63, 
95% confidence interval [CI] =0.46–0.87, P=0.004). Furthermore, using stratified analysis, 
LATS2 rs7317471 CT/TT genotypes were found to be significantly associated with decreased 
risk of death in patients who were below 53 years of age (adjusted HR =0.50), females (adjusted 
HR =0.60), smokers (adjusted HR =0.56), drinkers (adjusted HR =0.58), have Barcelona clinic 
liver cancer stage B (adjusted HR =0.62), and received no prior chemotherapy or transcatheter 
hepatic arterial chemoembolization (adjusted HR =0.48). Our results suggested that LATS2 
rs7317471 could be used as a potential biomarker for the prediction of HCC prognosis.
Keywords: hepatocellular carcinoma, LATS2, prognosis, retrospective study, single-nucleotide 
polymorphism
Introduction
Liver cancer is a prevalent gastrointestinal tract cancer in China, with a total of 355,595 
newly diagnosed cases and 322,417 deaths reported in 2011.1 The most common 
histological type of liver cancer is hepatocellular carcinoma (HCC). Even with the 
implementation of new treatment strategies including liver transplantation, surgical 
resection, chemotherapy, and molecular targeting therapy, the prognosis for HCC 
patients remains poor.2 To facilitate better management of HCC patients, it is crucial 
to identify specific biomarkers for prognosis prediction.
Hippo pathway is composed of a network of molecules that regulate HCC cell 
proliferation, apoptosis, migration, and differentiation.3 The core of the mamma-
lian Hippo pathway is a kinase cassette comprising mammalian STE20-like protein 
kinase 1/2 (MST1/2), salvador family WW domain containing protein 1 (SAV1), 
large tumor suppressor kinase 1/2 (LATS1/2), and MOB kinase activator 1 (MOB1). 
Upon activation of the Hippo pathway, MST1/2-SAV1 phosphorylates and activates 
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LATS1/2. The subsequent binding of LATS1/2 with MOB1 
will then phosphorylate the Yes-associated protein (YAP) and 
tafazzin (TAZ), leading to their cytoplasmic retention. In this 
way, excessive cell proliferation and tumorigenesis will be 
inhibited.4,5 When components of the core kinase cassette are 
dysregulated, hypophosphorylated YAP will be translocated 
into the nucleus and will directly interact with the transcrip-
tion factors, which will then induce a number of downstream 
gene expressions involving cell proliferation and cell death. 
As a result of excessive cell proliferation, aberrant YAP acti-
vation is associated with the development of multiple tumors 
including those of the liver,6 lung,7 ovary,8 colon–rectum,9 
pancreas,10 and prostate.11 Meanwhile, Hippo pathway may 
also be subject to regulation by any genetic alterations that 
manipulate the expression and function of its core components. 
An inactive cleaved form of MST1 was found in HCC tumors 
and correlated with low levels of phosphorylated YAP.12 The 
single-nucleotide polymorphism (SNP) of YAP rs1820453 
A.C may affect its expression levels and is associated with 
increased risk of breast cancer in the Chinese population.13 
This polymorphism was also found to be associated with 
reduced YAP expression and prognosis of small-cell lung 
cancer patients treated with platinum-based chemotherapy.14
To systematically investigate the clinical significance of 
genetic variations of Hippo pathway components in HCC, 
we performed SNP genotyping on 12 potentially functional 
genetic variants of the Hippo pathway in 331 HCC patients. 
Statistical analyses were performed to examine the prognostic 
value of each genetic variant in HCC.
Materials and methods
Patients
A total of 331 HCC patients were recruited from Nantong 
Tumor Hospital (Nantong, People’s Republic of China) and 
the First Affiliated Hospital of Nanjing Medical University, 
(Nanjing, People’s Republic of China) from January 2006 
to December 2010. Patients were diagnosed with HCC 
based on histopathological examination, or the measure-
ment of serological α-fetoprotein level (.400 ng/mL) and 
imaging examination by magnetic resonance imaging and/or 
computerized tomography, as described previously.15–17 In 
brief, patients enrolled in this study had either intermediate 
or advanced tumor stage according to Barcelona Clinic 
Liver Cancer (BCLC) staging system and tested positive 
for hepatitis B surface antigen.18 Patients were followed up 
every 3 months from the date of enrollment until death or to 
the last follow-up date (January 14, 2013). Individuals who 
smoked 1 cigarette per day for over 1 year were defined 
as smokers, and those who consumed one or more alcohol 
drinks a week for over 6 months were categorized as alcohol 
drinkers. None of them had received surgery. The study was 
approved by the institutional review board of Nanjing Medi-
cal University (Nanjing, People’s Republic of China). Signed 
informed consents were collected from enrolled patients for 
the use of clinical specimens in medical research.
serological tests
Surface antigen of hepatitis B virus (HBV), antibody against 
HBV surface antigen, antibody against HBV core antigen, and 
antibody against hepatitis C virus were detected by enzyme-
linked immunosorbent assays (Kehua Bio-Engineering Co., 
Ltd., Shanghai, People’s Republic of China), following the 
manufacturer’s instructions.19
selection and genotyping of snPs
Common SNPs associated with core components (of LATS1/2, 
MST1/2, SAV1,  MOB1, YAP, and TAZ) of Hippo signaling were 
included for initial analysis. The selected SNPs had minor allele 
frequency larger than 0.05 in Chinese/Asians and were located 
at the 5′ flanking regions, 5′-untranslated regions (5′-UTRs), 
coding regions, or 3′-UTRs according to NCBI dbSNP data 
(last search date: November 2014). We also included SNPs with 
biological significance or those that were associated with gene 
expression and/or cancer risk/survival according to the published 
literature. If SNPs are in high linkage disequilibrium (r2.0.8), 
we would genotype only one SNP. As a result, 12 SNPs 
(rs7317471 and rs9509492 in LATS2; rs4810446, rs2267853, 
rs8000, and rs6073627 in MST1; rs10955176 in MST2; and 
rs16861979, rs2043550, rs16861985, rs1055153, and rs7630434 
in TAZ) were selected for genotyping (Table 1).
Genomic DNA was extracted from a leukocyte pellet 
by traditional proteinase K digestion, phenol–chloroform 
extraction, and ethanol precipitation. All SNPs were geno-
typed using the Sequenom MassARRAY iPLEX platform 
(Sequenom, Inc., San Diego, CA, USA). All primers used 
are listed in Table S1. Two blank (water) controls in each 
384-well plate were performed for quality control, and more 
than 5% samples were randomly selected and the processes 
repeated, yielding a 100% concordance. The success rates 
of genotyping all 12 SNPs were above 95%.
statistical analyses
Survival time was calculated from the date of HCC diagnosis 
to the date of last follow-up or until death. Hardy–Weinberg 
equilibrium was assessed within patients by using a good-
ness-of-fit χ2 test. Median overall survival time (MOST) was 
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calculated, and mean survival time was presented when the 
MOST could not be calculated. Log-rank test was used to 
compare the survival time in different subgroups categorized 
by patient characteristics, clinical features, and genotypes. 
Univariate and multivariate Cox proportional hazard regres-
sion analyses were performed to estimate the crude or 
adjusted hazard ratio (HR) and their 95% confidence intervals 
(CIs), with adjustment of age, sex, smoking status, drinking 
status, BCLC tumor stage, and chemotherapy or interven-
tion status. The significance level was set at P,0.05, and 
P-values were two-sided. Analyses were carried out using 
the Statistical Analysis System software (version 9.1.3; SAS 
Institute, Cary, NC, USA).
Results
clinical features of the studied patient 
cohort
The demographic characteristics and clinical features of 
the 331 HCC patients were described previously.17 In this 
cohort, 284 (85.8%) patients were male and 47 (14.2%) 
were female. Three hundred and four patients (91.8%) had 
BCLC stage B disease, and 27 (8.2%) patients had BCLC 
stage C disease. Chemotherapy or interventional therapy 
was given to 91 patients (27.5%). The MOST of the cohort 
was 14.5 months. Patients who were defined as alcohol 
drinkers had a shorter median overall survival time (MOST, 
12.6 months) than nondrinkers (HR =1.43, 95% CI =1.11–
1.84, P=0.006). Compared to patients without chemotherapy 
or intervention (transcatheter arterial chemoembolization 
[TACE]) therapy (MOST =3.4 months), patients treated with 
chemotherapy or intervention therapy (MOST =16.8 months) 
had a decreased risk of death by 61% (HR =0.39, 95% 
CI =0.29–0.51, P,0.001).
snPs associated with patient survival in 
hcc
Kaplan–Meier and log-rank tests were used to examine the 
associations between the 12 studied SNPs and HCC survival 
by using different genetic models. All P-values of Hardy–
Weinberg equilibrium were greater than 0.05. As shown in 
Table 1, only LATS2 rs7317471 C.T polymorphism was 
significantly correlated with the overall survival time of 
HCC patients using the dominant model (Figure 1), while 
the rest of the SNPs were not found to have significant cor-
relations with the overall survival time. After adjusting for 
age, sex, smoking and drinking status, BCLC tumor stage, 
and chemotherapy or TACE status, LATS2 rs7317471 CT/TT 
genotypes remained significantly associated with favorable 
Table 1 genotyping results with 331 hcc patients’ survival
SNP Base  
changea
Gene Location Genotyping  
rate (%)
MAFb Reported  
MAFc
Log-rank P
Dominant  
model
Recessive  
model
Additive 
model
rs7317471 c.T LATS2 13q12.11 97.58 0.111 0.1082 0.034 0.563 0.104
rs9509492 a.g LATS2 13q12.11 96.07 0.361 0.3660 0.153 0.205 0.252
rs4810446 T.a MST1 20q13.12 96.68 0.213 0.1669 0.757 0.330 0.496
rs2267853 g.a MST1 20q13.12 96.37 0.097 0.0773 0.827 0.995 0.975
rs8000 a.c MST1 20q13.12 95.47 0.259 0.2629 0.780 0.949 0.962
rs6073627 c.g MST1 20q13.12 97.58 0.149 0.1804 0.196 0.541 0.285
rs10955176 T.c MST2 8q22.2 97.58 0.457 0.4639 0.660 0.766 0.894
rs16861979 c.T TAZ 3q25.1 96.68 0.437 0.4278 0.969 0.287 0.477
rs2043550 T.c TAZ 3q25.1 96.37 0.436 0.4072 0.285 0.131 0.090
rs16861985 c.g TAZ 3q25.1 96.37 0.183 0.1546 0.353 0.104 0.117
rs1055153 g.T TAZ 3q25.1 97.89 0.099 0.1082 0.735 0.073 0.163
rs7630434 T.c TAZ 3q25.1 96.37 0.217 0.2165 0.647 0.350 0.456
Notes: aMajor . minor allele; bMaF in 331 hcc patients; creported MAF in Han Chinese from 1,000 genomes. Bold value denotes statistical significance.
Abbreviations: hcc, hepatocellular carcinoma; snP, single nucleotide polymorphism; MaF, minor allele frequency.
Figure 1 Kaplan–Meier plots of survival by LATS2 rs7317471 genotypes in hcc 
patients’ survival (log-rank P=0.034 for cT/TT vs cc) in a dominant model.
Abbreviation: hcc, hepatocellular carcinoma.
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survival outcome (adjusted HR =0.63, 95% CI =0.46–0.87, 
P=0.004; Table 2) but not others.
To better assess the correlation between LATS2 
rs7317471 polymorphism and HCC survival, stratified 
analysis was performed on age, sex, smoking and drinking 
status, BCLC tumor stage, and chemotherapy or TACE 
status. As shown in Table 3, HCC patients who were younger 
than 53 years of age and had LATS2 rs7317471 CT/TT 
genotypes demonstrated longer overall survival (adjusted 
HR =0.50, 95% CI =0.31–0.81). Other stratified factors such 
as being female (adjusted HR =0.60, 95% CI =0.42–0.85) or 
smokers (adjusted HR =0.56, 95% CI =0.37–0.83) or drinkers 
(adjusted HR =0.58, 95% CI =0.38–0.87) or having BCLC 
stage B disease (adjusted HR =0.62, 95% CI =0.44–0.86) and 
having not received prior chemotherapy or TACE treatment 
(adjusted HR =0.48, 95% CI =0.25–0.91), all demonstrated 
similar outcomes.
Multivariate cox regression analysis on 
hcc survival
Multivariate Cox regression analysis was performed to 
analyze the effects of clinicopathological data, treatment, 
and LATS2 rs7317471 on HCC survival. In addition to age 
(P=0.005), chemotherapy or TACE treatment (P,0.001), 
drinking status (P=0.004), and LATS2 rs7317471 were 
found to be independent prognostic markers for the overall 
survival of HCC patients (HR =0.62, 95% CI =0.45–0.85, 
P=0.003; Table 4).
Discussion
In this study, we investigated the correlations between the 
functional polymorphisms of the core components in Hippo 
pathway with overall survival in 331 Chinese HCC patients. 
Among the 12 selected SNPs, eight SNPs were located in 
introns (rs4810446, rs2267853, rs8000, and rs6073627 in 
MST1; rs16861979, rs2043550, and rs16861985 in TAZ; 
and rs9509492 in LATS2), two of them (rs10955176 in 
MST2 and rs7630434 in TAZ) were located at the 3′-UTR, 
rs1055153 was located at the 5′ end of TAZ, and rs7317471 
was located in the coding region of LATS2. In this cohort, 
LATS2 rs7317471was found to be a prognostic biomarker 
for HCC survival in Chinese patients.
In our research, LATS2 rs7317471 C.T polymorphism 
correlated significantly with survival of HCC patients. Com-
pared to CC genotype, HCC patients with rs7317471 CT/TT 
genotypes tended to have a lower risk of death. This associa-
tion was more prominent in the subgroups of patients who 
were of younger age, were females, smokers, or drinkers, had 
BCLC tumor stage B, and did not receive chemotherapy or 
TACE treatments. In addition, multivariate Cox regression 
Table 2 genotypes of rs7317471 and 331 hcc patients’ survival
Genotype Patients Deaths MOST (months) Crude HR (95% CI) Adjusted HR (95% CI)a Pa
rs7317471
cc 255 206 13.34 1.00 1.00
cT 64 47 16.00 0.72 (0.52–0.99) 0.64 (0.46–0.88) 0.006
TT 4 2 18.96 0.62 (0.15–2.51) 0.51 (0.12–2.14) 0.358
Dominant model 0.71 (0.52–0.98) 0.63 (0.46–0.87) 0.004
recessive model 0.67 (0.17–2.68) 0.55 (0.13–2.31) 0.414
additive model 0.73 (0.54–0.98) 0.65 (0.48–0.87) 0.005
Note: aadjusted for age, sex, smoking and drinking status, Bclc stage, and chemotherapy or Tace status.
Abbreviations: HCC, hepatocellular carcinoma; MOST, median overall survival time; HR, hazard ratio; CI, confidence interval; BCLC, Barcelona Clinic Liver Cancer; TACE, 
transcatheter arterial chemoembolization. Bold value denotes statistical significance.
Table 3 Stratification analysis of rs7317471 genotypes associated 
with 331 hcc patients’ survival
Variables rs7317471 
(patients/ 
deaths)
Adjusted HR 
(95% CI)a
P for 
heterogeneity
CC CT/TT
age (years)
#53 138/113 30/22 0.50 (0.31–0.81) 0.289
.53 117/93 38/27 0.71 (0.46–1.10)
sex
Male 220/178 57/41 1.09 (0.46–2.55) 0.206
Female 35/28 11/8 0.60 (0.42–0.85)
smoking status
no 92/70 25/18 0.70 (0.41–1.19) 0.513
Yes 163/136 43/31 0.56 (0.37–0.83)
Drinking status
no 98/74 26/19 0.62 (0.36–1.05) 0.847
Yes 157/132 42/30 0.58 (0.38–0.87)
Bclc stage
stage B 235/189 61/44 0.62 (0.44–0.86) 0.865
stage c 20/17 7/5 0.69 (0.21–2.25)
chemotherapy or Tace
none 72/64 18/12 0.48 (0.25–0.91) 0.118
Yes 183/142 50/37 0.87 (0.60–1.26)
Note: aadjusted for age, sex, smoking and drinking status, Bclc stage, and 
chemotherapy or TACE status except for the stratification factor.
Abbreviations: hcc, hepatocellular carcinoma; Bclc, Barcelona clinic liver 
Cancer; HR, hazard ratio; CI, confidence interval; TACE, transcatheter hepatic 
arterial chemoembolization.
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analysis showed that LATS2 rs7317471 polymorphism was 
an independent biomarker for survival of HCC patients.
LATS2 is a serine/threonine kinase located on 
13q12.11.20–23 LATS2 acts as a putative tumor suppressor 
that controls G1/S and G2/M transition of the cell cycle.24,25 
Besides, it can also suppress antiapoptotic proteins Bcl-2 
and Bcl-XL to induce apoptosis as well as interacting with 
other cell division regulators, such as p53, to maintain mitotic 
fidelity and genetic stability.26,27 Hence, LATS2 malfunction 
will lead to aberrant cell proliferation, which is one of the 
hallmarks in cancer development and progression. LATS2 
expression is associated with several types of tumors includ-
ing breast cancer,13 prostate cancer,28 esophageal cancer, and 
colorectal cancer.29 Our study showed that LATS2 rs7317471 
C.T polymorphism was related with decreased risk of death 
in Chinese HCC patients, and it might also be associated with 
the aberrant expression or malfunction of LATS2 caused by 
this base change. Further research to investigate the function 
of this LATS2 variant is needed.
Conclusion
To our knowledge, this is the first study to investigate 
the association between SNPs of the core Hippo pathway 
components with HCC survival. Among the 12 SNPs, LATS2 
rs7317471 polymorphism decreased risk of death of HCC 
patients younger than 53 years of age, females, smokers, 
drinkers, those with BCLC stage B, and those who had 
not received chemotherapy or TACE. However, there are 
several limitations in our study. The results are based on a 
relatively small cohort of only 331 Chinese HBV-related HCC 
patients; further validation will be needed in a larger cohort. 
Meanwhile, the function of LATS2 rs7317471 has not been 
characterized. Investigating the consequence of this polymor-
phism on LATS2 expression and function as well as examin-
ing the correlations between LATS2 rs7317471 genotypes and 
the alterations of Hippo pathway components may help to 
reveal the functional role of this polymorphism. In summary, 
our results indicate that LATS2 rs7317471 could be a potential 
prognostic biomarker for HCC patients in China.
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Notes: aβ is the estimated parameter of the regression model. bse is the standard error of the regression model.
Abbreviations: hcc, hepatocellular carcinoma; β, estimated parameter; SE, standard error; HR, hazard ratio; CI, confidence interval; TACE, transcatheter hepatic arterial 
chemoembolization. Bold value denotes statistical significance.
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genetic variant of LATS2 predicts prognosis in hepatocellular carcinoma
Table S1 Primers and probes for sequenom allelic discrimination
Polymorphism Sequence (5′–3′)
rs7317471
2nd-Pcr primer acgTTggaTggaagTgTcacTgTTTggTcc
1st-Pcr primer acgTTggaTggacTgcaagagaTTcgTgag
extend primer aagacTTggaTggcTg
rs9509492
2nd-Pcr primer acgTTggaTgcTTaTTTgTTagcggaTgcc
1st-Pcr primer acgTTggaTgggagaagaaTTTccTgccgT
extend primer TTagcggaTgccTTTTTTT
rs4810446
2nd-Pcr primer acgTTggaTgcacTgTaggaTggcaTcTTT
1st-Pcr primer acgTTggaTgTaccTaccTcccaaTgTcag
extend primer gggaTgaTgTTcagTgTcTTccTaa
rs2267853
2nd-Pcr primer acgTTggaTgcacacaggaTTgTTgTgagg
1st-Pcr primer acgTTggaTgTgTgTccTgcTgaagcaTaT
extend primer gTgTgaggTTcaaaTgagTT
rs8000
2nd-Pcr primer acgTTggaTggTTaaagcTacaaacTTcac
1st-Pcr primer acgTTggaTgcTTTTaccagcTTgcacTcg
extend primer caTTTTTaaacTgTacaTagcaa
rs6073627
2nd-Pcr primer acgTTggaTgTccTcTgTTTTccgTaTccg
1st-Pcr primer acgTTggaTggcaagaggcagTTgTTagTc
extend primer cgccacaTagcTaTTTca
rs10955176
2nd-Pcr primer acgTTggaTgTgcTgTgcaTTcacTcTaag
1st-Pcr primer acgTTggaTgTggTaTgcagcTgacagaac
extend primer cTcgaagaTgaggagaacaaaagaa
rs16861979
2nd-Pcr primer acgTTggaTgcTgaTTaaggcacagagTag
1st-Pcr primer acgTTggaTggTTaccaaTTTcTaaccTcc
extend primer TaggcacTaaaTacaTTcTccc
rs2043550
2nd-Pcr primer acgTTggaTgTTcagTTTccaaaagcTggg
1st-Pcr primer acgTTggaTggcTTTcccTTcaggcaTTTc
extend primer cTagcTgggcccTgTTca
rs16861985
2nd-Pcr primer acgTTggaTgcaggTgTaaaTcgTTTcTgac
1st-Pcr primer acgTTggaTgacccagacacTcTTgaTgcT
extend Primer acacTcgTTTcTgacTTaTgTgcagac 
Abbreviation: Pcr, polymerase chain reaction.
Supplementary material
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